EFOEUPATI

Ensuring the future of EUPATI beyond 2020

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 11
Grant agreement number
806995

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
365 243
EFPIA in kind
238 800
Total Cost
604 043

Summary

IMI’s EUPATI project delivered a wealth of resources to support and educate patients who wish to become more involved in medical research and drug development. These include the patient expert training course, the online multilingual toolbox, and the network of national platforms. The goal of EFOEUPATI is to develop a viable business model to ensure the viability of these resources in the medium to long term. Among other things, the project will create a patient education and engagement portal that will host relevant information and resources for patients and other stakeholders. This will ultimately replace the current EUPATI website. EFOEUPATI will also strengthen the coordination and impact of the existing EUPATI national platform network by promoting collaboration and knowledge exchange.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • European Forum For Good Clinical Practice, Brussels, Belgium
  • Irish Platform For Patients' Organisations Science And Industry Limited By Guarantee, Dublin, Ireland
  • Kobenhavns Universitet, Copenhagen, Denmark
Patient organisations
  • European Aids Treatment Group Ev, Duesseldorf, Germany
  • European Patients’ Forum (EPF), Brussels, Belgium

CONTACT

Project coordinator
Matthew MAY
FORUM EUROPEEN DES PATIENTS (FPE)
matthew.may[at]eu-patient.eu